Depressive disorders are currently diagnosed based on the ICD-10 and DSM-5 diagnostic criteria and include axial depressive symptoms and additional symptoms that must coexist for at least two weeks. Migraine is diagnosed based on the International Classification of Headache Disorders. It is generally divided into migraine with and without aura, and with regard to the frequency of attacks into episodic and chronic migraine. The therapeutic strategy in the treatment of depression is pharmacotherapy combined with psychotherapy, whereas in the treatment of migraine the strategy depends on the frequency of headache attacks (episodic migraine vs. chronic migraine) and comorbidities. A novelty is the introduction of monoclonal antibodies directed against CGRP or the receptor of CGRP. There are numerous reports which indicate specific usefulness of monoclonal antibodies that modify the action of CGRP in the treatment of migraine in people suffering from depression.

Download full-text PDF

Source
http://dx.doi.org/10.12740/PP/OnlineFirst/139596DOI Listing

Publication Analysis

Top Keywords

migraine
8
diagnosed based
8
attacks episodic
8
chronic migraine
8
treatment migraine
8
monoclonal antibodies
8
experts national
4
national consultants'
4
consultants' recommendations
4
recommendations management
4

Similar Publications

Previous observational studies have suggested at a potential link between migraine, particularly migraine with aura, and the susceptibility to early-onset ischemic stroke. We aimed to investigate the causal effects of genetically determined migraine and its subtypes on the risk of early-onset ischemic stroke using the two-sample Mendelian randomization method. Genetic instrumental variables associated with migraine and its subtypes were acquired from two sources with the largest sample sizes available.

View Article and Find Full Text PDF

Objective: To evaluate the relationship of diet and food components with the frequency of migraine attacks.

Material And Methods: Sixty patients (mean age 35.5±8.

View Article and Find Full Text PDF

Objective: To develop and assess the psychometrics of the Chronic Headache Self-Efficacy Scale (CHASE).

Background: Existing scales assess self-efficacy in coping strategies and management of symptoms and triggers but do not measure other important self-efficacy domains, such as performing daily activities and socializing in patients with chronic daily headache (CDH).

Methods: The study had two phases: (i) Development of the 14-item CHASE, with items derived from patients with CDH and a multidisciplinary healthcare team; (ii) longitudinal observational study for psychometric evaluation.

View Article and Find Full Text PDF

General physical impairments in migraine patients beyond cervical function.

Sci Rep

December 2024

Departamento de Cirugía, Ciencias Médicas y Sociales, Facultad de Medicina, Universidad de Alcalá, Alcalá de Henares, Spain.

Previous research has focused on the possibility of cervical dysfunction in migraine patients, similar to what is observed in patients with tension-type headaches. However, there is no evidence concerning the physical function of other body regions, even though lower levels of physical activity have been reported among migraine patients. The aim of this study was to compare cervical and extra-cervical range of motion, muscular strength, and endurance, as well as overall levels of physical activity, between patients with chronic migraine (CM) and asymptomatic participants.

View Article and Find Full Text PDF

Botulinum Toxin and Migraine: Goals and Perspectives.

Toxins (Basel)

December 2024

Headache Center, Neurological Clinic, "L. Amaducci", AOUC Policlinico, Piazza G. Cesare, 11, 70124 Bari, Italy.

This Special Issue aims to provide an updated overview of the current state and future perspectives of botulinum toxin treatment for migraine [...

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!